Our Science – Hurwitz Website
Arthur Andrew Hurwitz, Ph.D.
Selected Publications |
 |
| 1)
Zhu Z, Singh V, Watkins SK, Bronte V, Shoe JL, Feigenbaum L, Hurwitz AA. High-avidity T cells are preferentially tolerized in the tumor microenvironment. Cancer Res. 73: 595-604, 2013. [Journal] |
|
| 2)
Watkins SK, Hurwitz AA. FOXO3: A master switch for regulating tolerance and immunity in dendritic cells. Oncoimmunology. 1: 252-254, 2012. [Journal] |
|
| 3)
Hurwitz AA, Watkins SK. Immune suppression in the tumor microenvironment: a role for dendritic cell-mediated tolerization of T cells. Cancer Immunol. Immunother. 61: 289-93, 2012. [Journal] |
|
| 4)
Watkins SK, Zhu Z, Watkins KE, Hurwitz AA. Isolation of immune cells from primary tumors. J Vis Exp. e3952, 2012. [Journal] |
|
| 5)
Hudson RS, Yi M, Esposito D, Watkins SK, Hurwitz AA, Yfantis HG, Lee DH, Borin JF, Naslund MJ, Alexander RB, Dorsey TH, Stephens RM, Croce CM, Ambs S. MicroRNA-1 is a candidate tumor suppressor and prognostic marker in human prostate cancer. Nucleic Acids Res. 40: 3689-703, 2012. [Journal] |
|
| 6)
Hudson RS, Yi M, Esposito D, Glynn SA, Starks AM, Yang Y, Schetter AJ, Watkins SK, Hurwitz AA, Dorsey TH, Stephens RM, Croce CM, Ambs S. MicroRNA-106b-25 cluster expression is associated with early disease recurrence and targets caspase-7 and focal adhesion in human prostate cancer. Oncogene. [Epub ahead of print], 2012. [Journal] |
|
| 7)
Watkins SK, Zhu Z, Riboldi E, Shafer-Weaver KA, Stagliano KE, Sklavos MM, Ambs S, Yagita H, Hurwitz AA. FOXO3 programs tumor-associated DCs to become tolerogenic in human and murine prostate cancer. J. Clin. Invest. 121: 1361-72, 2011. [Journal] |
|
| 8)
Chen X, Hamano R, Subleski JJ, Hurwitz AA, Howard OM, Oppenheim JJ. Expression of costimulatory TNFR2 induces resistance of CD4(+)FoxP3(-) conventional T cells to suppression by CD4(+)FoxP3(+) regulatory T Cells. J. Immunol. 185: 174-82, 2010. [Journal] |
|
| 9)
Shafer-Weaver KA, Anderson MJ, Stagliano K, Malyguine A, Greenberg NM, Hurwitz AA. Cutting Edge: Tumor-specific CD8+ T cells infiltrating prostatic tumors are induced to become suppressor cells. J. Immunol. 183: 4848-52, 2009. [Journal] |
|
| 10)
Shafer-Weaver KA, Watkins SK, Anderson MJ, Draper LJ, Malyguine A, Alvord WG, Greenberg NM, Hurwitz AA. Immunity to murine prostatic tumors: continuous provision of T-cell help prevents CD8 T-cell tolerance and activates tumor-infiltrating dendritic cells. Cancer Res. 69: 6256-64, 2009. [Journal] |
|
| Click Here to View Expanded Bibliography. |
This page was last updated on 4/11/2013.
